Literature DB >> 31171223

Urinary metabolomic signature of muscle-invasive bladder cancer: A multiplatform approach.

Julia Jacyna1, Renata Wawrzyniak1, Stéphane Balayssac2, Véronique Gilard2, Myriam Malet-Martino2, Aleksandra Sawicka1, Marta Kordalewska1, Łukasz Nowicki3, Eliza Kurek4, Ewa Bulska4, Małgorzata Patejko1, Marcin Markuszewski5, Piotr Gutknecht6, Marcin Matuszewski5, Janusz Siebert6, Roman Kaliszan1, Michał J Markuszewski7.   

Abstract

Bladder cancer (BCa) is ninth amongst the most common types of cancer in the human population worldwide. The statistics of incidence and mortality of BCa are alarming and the currently applied diagnostic methods are still not sensitive enough. This leads to a large number of undiagnosed BCa cases, usually among patients in the early stages of the disease. Despite the fact that many risk factors of BCa have been recognized, the pathomechanism of development of bladder cancer has not been fully explained yet. Therefore, in the present study, multiplatform urinary metabolomics has been implemented in order to scrutinize potential diagnostic indicators of BCa that might help to explain its pathomechanism and be potentially useful in diagnosis and determination of stage of the disease. Urine samples collected from muscle-invasive high grade BCa patients (n = 24) and healthy volunteers (n = 24) were matched in terms of most common BCa risk factors i.e. gender, age, BMI and smoking status. They were analyzed by high performance liquid chromatography coupled with time of flight mass spectrometry detection (HPLC-TOF/MS) using RP and HILIC chromatography, gas chromatography hyphenated with triple quadruple mass spectrometry detection (GC-QqQ/MS) in scan mode, and proton nuclear magnetic resonance (1H NMR). The six datasets obtained were submitted to univariate and multivariate statistical analyses. 17 metabolites significantly discriminated urinary profiles of BCa patients from urinary profiles of healthy volunteers. These metabolites are mainly involved in amino acid metabolism, pyrimidine and purine metabolism, as well as energy metabolism and might play a crucial role in the pathogenesis of BCa.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bladder cancer; GC-MS; LC-MS; Metabolomics; NMR

Mesh:

Year:  2019        PMID: 31171223     DOI: 10.1016/j.talanta.2019.05.039

Source DB:  PubMed          Journal:  Talanta        ISSN: 0039-9140            Impact factor:   6.057


  4 in total

1.  Metabolic Profiling of Bladder Cancer Patients' Serum Reveals Their Sensitivity to Neoadjuvant Chemotherapy.

Authors:  Juntao Zhuang; Xiao Yang; Qi Zheng; Kai Li; Lingkai Cai; Hao Yu; Jiancheng Lv; Kexin Bai; Qiang Cao; Pengchao Li; Haiwei Yang; Junsong Wang; Qiang Lu
Journal:  Metabolites       Date:  2022-06-17

Review 2.  Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer.

Authors:  Nicola Antonio di Meo; Davide Loizzo; Savio Domenico Pandolfo; Riccardo Autorino; Matteo Ferro; Camillo Porta; Alessandro Stella; Cinzia Bizzoca; Leonardo Vincenti; Felice Crocetto; Octavian Sabin Tataru; Monica Rutigliano; Michele Battaglia; Pasquale Ditonno; Giuseppe Lucarelli
Journal:  Int J Mol Sci       Date:  2022-04-10       Impact factor: 6.208

3.  Pre- and Post-Resection Urine Metabolic Profiles of Bladder Cancer Patients: Results of Preliminary Studies on Time Series Metabolomics Analysis.

Authors:  Julia Jacyna; Marta Kordalewska; Małgorzata Artymowicz; Marcin Markuszewski; Marcin Matuszewski; Michał J Markuszewski
Journal:  Cancers (Basel)       Date:  2022-02-25       Impact factor: 6.639

4.  Analysis of VOCs in Urine Samples Directed towards of Bladder Cancer Detection.

Authors:  Tomasz Ligor; Przemysław Adamczyk; Tomasz Kowalkowski; Ileana Andreea Ratiu; Anna Wenda-Piesik; Bogusław Buszewski
Journal:  Molecules       Date:  2022-08-07       Impact factor: 4.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.